Cargando…
Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand
BACKGROUND: In Thailand, pharmaceutical care has been recently introduced to a tertiary hospital as an approach to improve adherence to tuberculosis (TB) treatment in addition to home visit and modified directly observed therapy (DOT). However, the economic impact of pharmaceutical care is not known...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103920/ https://www.ncbi.nlm.nih.gov/pubmed/29623626 http://dx.doi.org/10.1007/s41669-017-0053-0 |
_version_ | 1783349389979287552 |
---|---|
author | Tanvejsilp, Pimwara Loeb, Mark Dushoff, Jonathan Xie, Feng |
author_facet | Tanvejsilp, Pimwara Loeb, Mark Dushoff, Jonathan Xie, Feng |
author_sort | Tanvejsilp, Pimwara |
collection | PubMed |
description | BACKGROUND: In Thailand, pharmaceutical care has been recently introduced to a tertiary hospital as an approach to improve adherence to tuberculosis (TB) treatment in addition to home visit and modified directly observed therapy (DOT). However, the economic impact of pharmaceutical care is not known. OBJECTIVE: The aim of this study was to estimate healthcare resource uses and costs associated with pharmaceutical care compared with home visit and modified DOT in pulmonary TB patients in Thailand from a healthcare sector perspective inclusive of out-of-pocket expenditures. METHODS: We conducted a retrospective study using data abstracted from the hospital billing database associated with pulmonary TB patients who began treatment between 2010 and 2013 in three hospitals in Thailand. We used generalized linear models to compare the costs by accounting for baseline characteristics. All costs were converted to international dollars (Intl$) RESULTS: The mean direct healthcare costs to the public payer were $519.96 (95%confidence interval [CI] 437.31–625.58) associated with pharmaceutical care, $1020.39 (95% CI 911.13–1154.11) for home visit, and $887.79 (95% CI 824.28–955.91) for modified DOT. The mean costs to patients were $175.45 (95% CI 130.26–230.48) for those receiving pharmaceutical care, $53.77 (95% CI 33.25–79.44) for home visit, and $49.33 (95% CI 34.03–69.30) for modified DOT. After adjustment for baseline characteristics, pharmaceutical care was associated with lower total direct costs compared with home visit (−$354.95; 95% CI −285.67 to −424.23) and modified DOT (−$264.61; 95% CI −198.76 to −330.46). CONCLUSION: After adjustment for baseline characteristics, pharmaceutical care was associated with lower direct costs compared with home visit and modified DOT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s41669-017-0053-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6103920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-61039202018-08-27 Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand Tanvejsilp, Pimwara Loeb, Mark Dushoff, Jonathan Xie, Feng Pharmacoecon Open Original Research Article BACKGROUND: In Thailand, pharmaceutical care has been recently introduced to a tertiary hospital as an approach to improve adherence to tuberculosis (TB) treatment in addition to home visit and modified directly observed therapy (DOT). However, the economic impact of pharmaceutical care is not known. OBJECTIVE: The aim of this study was to estimate healthcare resource uses and costs associated with pharmaceutical care compared with home visit and modified DOT in pulmonary TB patients in Thailand from a healthcare sector perspective inclusive of out-of-pocket expenditures. METHODS: We conducted a retrospective study using data abstracted from the hospital billing database associated with pulmonary TB patients who began treatment between 2010 and 2013 in three hospitals in Thailand. We used generalized linear models to compare the costs by accounting for baseline characteristics. All costs were converted to international dollars (Intl$) RESULTS: The mean direct healthcare costs to the public payer were $519.96 (95%confidence interval [CI] 437.31–625.58) associated with pharmaceutical care, $1020.39 (95% CI 911.13–1154.11) for home visit, and $887.79 (95% CI 824.28–955.91) for modified DOT. The mean costs to patients were $175.45 (95% CI 130.26–230.48) for those receiving pharmaceutical care, $53.77 (95% CI 33.25–79.44) for home visit, and $49.33 (95% CI 34.03–69.30) for modified DOT. After adjustment for baseline characteristics, pharmaceutical care was associated with lower total direct costs compared with home visit (−$354.95; 95% CI −285.67 to −424.23) and modified DOT (−$264.61; 95% CI −198.76 to −330.46). CONCLUSION: After adjustment for baseline characteristics, pharmaceutical care was associated with lower direct costs compared with home visit and modified DOT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s41669-017-0053-0) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-08-22 /pmc/articles/PMC6103920/ /pubmed/29623626 http://dx.doi.org/10.1007/s41669-017-0053-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Tanvejsilp, Pimwara Loeb, Mark Dushoff, Jonathan Xie, Feng Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand |
title | Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand |
title_full | Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand |
title_fullStr | Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand |
title_full_unstemmed | Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand |
title_short | Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand |
title_sort | healthcare resource uses and out-of-pocket expenses associated with pulmonary tb treatment in thailand |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103920/ https://www.ncbi.nlm.nih.gov/pubmed/29623626 http://dx.doi.org/10.1007/s41669-017-0053-0 |
work_keys_str_mv | AT tanvejsilppimwara healthcareresourceusesandoutofpocketexpensesassociatedwithpulmonarytbtreatmentinthailand AT loebmark healthcareresourceusesandoutofpocketexpensesassociatedwithpulmonarytbtreatmentinthailand AT dushoffjonathan healthcareresourceusesandoutofpocketexpensesassociatedwithpulmonarytbtreatmentinthailand AT xiefeng healthcareresourceusesandoutofpocketexpensesassociatedwithpulmonarytbtreatmentinthailand |